Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Autoimmune disorders in interferon therapy]

T Okanoue1, Y Itoh, K Yasui

  • 1Third Department of Internal Medicine, Kyoto Prefectural University of Medicine.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|July 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply to the Letter to the editor 'Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus Sorafenib for advanced hepatocellular carcinoma: randomized phase II trial' by Fornaro et al.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Clinical utility of the basophil activation test for analysis of allergic transfusion reactions: a pilot study.

Vox sanguinis·2017
Same author

Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Combination of Sonodynamic and Photodynamic Therapy against Cancer Would Be Effective through Using a Regulated Size of Nanoparticles.

Nanoscience and nanoengineering·2016
Same author

Comparison of neutralization profiles for anti-HCV reactive donor samples with or without detectable HCV RNA.

Vox sanguinis·2015
Same author

The association between risk factors and time of onset for thrombocytopenia in Japanese patients receiving linezolid therapy: a retrospective analysis.

Journal of clinical pharmacy and therapeutics·2015
Same journal

[Development of novel therapeutics for multiple myeloma and improvement of drug lag].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Clinical pharmacy services to patients of immunomodulatory drugs].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Therapeutic drug monitoring of the new anti-myeloma drugs in the treatment of multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[The evaluation of minimal residual disease in multiple myeloma by an allele-specific oligonucleotide real-time PCR].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Evaluation of minimal residual disease in myeloma by multiparametric flow cytometry].

Nihon rinsho. Japanese journal of clinical medicine·2019
See all related articles

Interferon (IFN) therapy can trigger autoimmune disorders like SLE and rheumatoid arthritis, particularly in patients with pre-existing immune issues. However, these conditions often improve after discontinuing IFN treatment.

Area of Science:

  • Immunology
  • Hepatology
  • Pharmacology

Background:

  • Interferons (IFNs) possess immunomodulatory effects, influencing immune cell activity and antigen expression.
  • IFN therapy is known to potentially induce autoimmune disorders, although some, like autoimmune thyroiditis, are more common than others.

Observation:

  • This study investigated autoimmune disorders in 1023 patients with chronic active hepatitis C undergoing IFN treatment.
  • A significant observation was that patients with predisposing immunological abnormalities, such as positive antinuclear antibodies (ANA), were more prone to developing these side effects.

Findings:

  • Interferon therapy can induce various autoimmune conditions, including systemic lupus erythematosus (SLE), thrombocytopenic purpura, rheumatoid arthritis, and psoriasis.
  • While autoimmune thyroiditis is a known side effect, other autoimmune diseases induced by IFN are relatively rare.

Related Experiment Videos

  • Importantly, patients experiencing SLE, thrombocytopenic purpura, rheumatoid arthritis, and psoriasis showed good prognoses following the cessation of IFN administration.

    • Implications:

    • IFN treatment requires careful monitoring for autoimmune side effects, especially in patients with latent immunological predispositions.
    • Discontinuation of IFN therapy can lead to favorable outcomes for induced autoimmune diseases, suggesting a reversible mechanism.
    • Understanding these associations aids in managing patients undergoing IFN therapy for chronic hepatitis C and other conditions.